Four-year follow-up of the phase 3 POLLUX study of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in relapsed or refractory multiple myeloma

Autores: Cook, G.; Kaufman, J. L.; Usmani, S. Z.; San Miguel Izquierdo, Jesús; Bahlis, N. J.; White, D. ; Benboubker, L.; Leiba, M.; Ho, P. J.; Kim, K.; Takezako, N.; Moreau, P.; Krevvata, M.; Pei, H.; Ukropec, J.; Renaud, T.; Trivedi, S.; Kobos, R. ; Dimopoulos, M. A.